-
US Open resumes after two-hour fog delay
-
The vaccines and treatments being developed for Ebola outbreak
-
Spanish king to visit Mexican president on June 25 as ties improve
-
Ton-up Phillips stars for New Zealand against England
-
Wahi denied Canadian visa for Ivory Coast World Cup clash with Germany
-
Swiss central bank holds interest rates, with eye on currency risks
-
S.African sentenced in 'world's largest' rhino trafficking case
-
Bank of England follows Fed in holding interest rate
-
Bittersweet World Cup for Gaza's football fans
-
Trump defends Iran deal from critics he calls 'fools'
-
New heatwave disrupts trains, schools in France
-
German chemical company to cut 3,200 jobs as crisis worsens
-
Starmer's Labour rival eyes win in UK poll key to PM's fate
-
Mexico, Korea eye World Cup knockout berths
-
Range raises $8.3M Series A to unify treasury, risk and compliance across stablecoins and fiat
-
IAEA ready to help define 'concrete steps' to implement US-Iran deal
-
Ibrahima Konate signs four-year deal with Real Madrid
-
Hegseth tells NATO US will review force presence in Europe
-
Innovations on show at Paris Vivatech fest
-
Ukraine sets Moscow refinery ablaze in biggest attack in years
-
Bird flu kills 13,000 seal pups on remote Australian island
-
Oil prices sink further as Trump signs deal to reopen Hormuz
-
South Korean lawmakers launch probe into ballot paper shortages
-
Starmer rival seeks win in UK poll pivotal to PM's fate
-
Taiwan president says hopes for $14 bn US arms sale 'as soon as possible'
-
Why are Kenyan kids burning schools and killing their classmates?
-
New wave of anti-LGBTQ laws sweeps Africa
-
Ukraine hopes renewables can Russia-proof power grid
-
Jubilant New York on guard for Knicks parade
-
What we learned after the first round of World Cup games
-
New Zealander Manu has 'no fear' of Toulouse before Top 14 semi
-
Drastic restrictions on public transport take effect in Cuba
-
Pain-riddled South Korean man fights for right to die
-
Cuba approves economic reforms to boost private sector, investment: state TV
-
India learns to live with hotter summers
-
'Retired' Wallaby Slipper, 37, set for shock international comeback
-
EU wrestles over how to tackle China export flood
-
Tartan Army takes over Boston as Scotland fans relish World Cup return
-
Comedian Jordan Klepper wishes satire was harder in age of Trump
-
Robots pour cocktails and run marathons, but still can't multitask
-
Birthright citizenship helps spark US World Cup run
-
Ghana beat Panama 1-0 in World Cup opener after injury-time winner
-
Castro gives crucial backing to Cuba reforms
-
BlockFuel Energy Launches Vertical Drilling Program for Second Half 2026
-
Tiderock Companies, Inc. Announces Five-Year Lease Signing for UK Composite Manufacturing Facility
-
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026
-
The New Era of Independent Luxury in Mexico: Industry Leaders Redefine Hospitality Distribution at the Mexican Hospitality Summit
-
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
-
Driving the World's Leading Supply Chains: 9 OMP Customers Named to The 2026 Gartner Top 25
-
Razavi Law Group Invests in Orange County's Next Generation of Mental Health Leaders
Four Independent Studies Validate The Blight Tolerance Of Darling American Chestnut Trees
New data demonstrate that transgenic American chestnuts produce significantly smaller blight cankers than their wild-type counterparts
MCGRAW, NY / ACCESS Newswire / April 25, 2026 / Today, SilvaBio, in collaboration with academic partners, reports findings from four independent experiments demonstrating that transgenic American chestnut trees consistently tolerate blight, the fungal disease that rendered the species functionally extinct in the early 19th century. This expanding body of evidence-spanning studies conducted by Purdue University, the University of New England (UNE) and SUNY College of Environmental Science and Forestry (ESF)-provides validation of the single-transgene approach and reinforces its application for restoration of this keystone species across its native range.
American chestnut trees (Castanea dentata) carrying the oxalate oxidase (OxO) transgene consistently develop smaller blight cankers than their wild-type counterparts after deliberate exposure to chestnut blight fungus, when measured under comparable conditions at each site. Across six separate comparisons-conducted by multiple research groups using varied experimental designs, inoculation protocols, and pathogen strains-the transgenic trees produced cankers 30% to 81% smaller, providing robust evidence that validates blight tolerance.
In addition, at three sites, Chinese chestnuts were tested alongside transgenic American chestnuts under identical inoculation conditions. While Chinese chestnut trees are considered to provide the "gold-standard" comparison for blight tolerance, transgenic trees performed comparably to their Chinese counterparts.
Collectively, these results provide the most comprehensive evidence to date that the OxO transgene confers reproducible, meaningfully enhanced blight resistance under controlled conditions.
According to Dr. Andrew Newhouse, Ph.D., director of the chestnut research program at ESF, "These results confirm that Darling American chestnuts can tolerate blight infections in multiple outdoor environments. We are proud to work with this team of partners and collaborators, and look forward to continued progress on this critical conservation project."
"At the University of New England, we have arrived at a body of evidence indicating that the American chestnuts carrying the OxO gene are better able to tolerate the fungal blight compared to their full sibling counterparts without the gene," said Dr. Thomas Klak, Ph.D., professor in the School of Marine and Environmental Programs. "We see no negative impacts on maturation from carrying the OxO gene and good field performance by the OxO trees when inoculated with a virulent strain of the blight."
"For over a century, the American chestnut has been absent from our forests. These four independent studies offer the strongest evidence to date that we are on the right path to restore it," said Michael Bloom, SilvaBio CEO.
John Dougherty, American Chestnut Restoration Vice President for Science, "These studies confirm that the ESF lab and green house screens successfully predicted that Darling has sustainable blight tolerance performance in field trials that is equal to or better than Chinese standard."
Results by Site
Across multiple independent field and experimental trials, transgenic American chestnut trees consistently developed substantially smaller blight cankers than non-transgenic controls.
University of New England (UNE): Transgenic trees showed ~30-36% reductions in canker length across two years of trials.
Purdue University: Across large, multi-year field trials, transgenic trees exhibited ~46-50% reductions in canker area.
SUNY College of Environmental Science and Forestry (ESF):
In young seedlings, transgenic trees had up to 81% smaller cankers than wild-type trees.
In older field-grown trees, reductions remained substantial at ~62%.
Background
Once a cornerstone of eastern forests, the American chestnut made up as much as a quarter of the canopy across its 25-state native range. In the early 1900s, a fungal blight killed an estimated 4 billion trees, rendering the species functionally extinct within decades and leaving a lasting ecological and economic void. After years of research, scientists at SUNY ESF developed the first blight-tolerant, fully American chestnut, known as "Darling 54," marking a major breakthrough built on ongoing collaboration among American Chestnut Restoration Inc., SilvaBio, and other partners.
Building on this work, SilvaBio is advancing restoration by moving the Darling line from the lab to scalable, real-world deployment. Using genomic prediction, accelerated breeding, and advanced micropropagation, the company is developing and producing a robust, genetically-diverse range of resilient seedlings for forest-scale reintroduction. These capabilities enable earlier selection of disease-tolerant trees, compress breeding timelines, and support large-scale production needed for meaningful restoration, pending deregulation.
Together, these findings support the effectiveness of the OxO-based transgenic approach as a viable path to restoring the American chestnut and provide the scientific foundation for extending this platform to other at-risk species, including ash, oak, and elm.
To learn more about the Darling 54 American chestnut restoration project, please visit https://www.restorechestnut.org/.
To learn more about SilvaBio, please visit https://www.silvabio.com/.
###
About SilvaBio
SilvaBio is a biotechnology company addressing hardwood tree disease, beginning with the restoration of the American chestnut and expanding to other threatened species such as ash and elm. U.S. forests contribute over $350 billion annually and absorb nearly 15% of national carbon emissions, yet invasive diseases are outpacing traditional restoration. SilvaBio combines advanced genomics, accelerated breeding ("Lightspeed"), and proprietary micropropagation to develop resilient, regionally adapted trees and scale their deployment-enabling restoration at the scale our forests require. To learn more, please visit https://www.silvabio.com/.
About SUNY College of Environmental Science & Forestry
The SUNY College of Environmental Science and Forestry (ESF) is dedicated to the study of the environment, developing renewable technologies, and building a sustainable and resilient future through design, policy, and management of the environment and natural resources. Members of the College community share a passion for protecting the health of the planet and a deep commitment to the rigorous application of science to improve the way humans interact with the mo world. The College offers academic programs ranging from the associate of applied science to the Doctor of Philosophy. ESF students live, study and do research on the main campus in Syracuse, N.Y., and on 25,000 acres of field stations in a variety of ecosystems across the state. To learn more, please visit https://www.esf.edu/chestnut/.
About The University of New England
The University of New England is Maine's largest independent university, with campuses in Biddeford and Portland, Maine, a campus in Tangier, Morocco, and a robust array of online programs. UNE combines rigorous academic preparation with hands-on, purpose-driven learning in health, science, marine and environmental studies, and the liberal arts. As Maine's leading provider of health professionals, UNE prepares students to address the interconnected challenges of human and planetary health in a rapidly changing world. To learn more, please visit https://www.une.edu/.
Media Contact:
Sheila Smith,
Communications Director, SilvaBio
[email protected]
203.917.8644
Data Sources
Klak, T., Travis, S., May, V. G., Tan, E. H., Chatfield, M. W. H., & Wheeler, M. (2025). Two-year field trial of genetically engineered American chestnut reveals greater fungal blight tolerance compared to wild-type full-sibling trees. bioRxiv.
Kell, C. (2025). Two-year field screening of Darling 54 transgenic American chestnut progeny in the Central Hardwood region. Hardwood Tree Improvement and Regeneration Center, Purdue University. Public comment in support of Darling 54 deregulation, APHIS Docket No. APHIS-2020-0030-19913.
ESF Darling Science Update (2023). Available at: https://www.esf.edu/chestnut/science-update/index.php.
SOURCE: SilvaBio
View the original press release on ACCESS Newswire
A.Malone--AMWN